Neoadjuvant personalized cancer vaccines: the final frontier?
ABSTRACTIntroduction Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens. However, their use has been traditionally restricted to adjuvant settings and la...
Main Authors: | Guilhem Richard, Nicole Ruggiero, Gary D. Steinberg, William D. Martin, Anne S. De Groot |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2303015 |
Similar Items
-
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition
by: Annie Borch, et al.
Published: (2024-04-01) -
Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis
by: Guadalupe Nibeyro, et al.
Published: (2023-07-01) -
Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
by: Lavinia Gatteschi, et al.
Published: (2021-10-01) -
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
by: Kaïdre Bendjama, et al.
Published: (2017-09-01) -
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
by: David Repáraz, et al.
Published: (2022-02-01)